Data Insights

Efgartigimod alfa by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Pre-Registration for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Data Insights

Efgartigimod alfa by Argenx for Bullous Pemphigoid: Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Bullous Pemphigoid

Data Insights

Efgartigimod alfa by Argenx for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Data Insights

Efgartigimod alfa by Argenx for Dermatomyositis: Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Dermatomyositis

Data Insights

Efgartigimod alfa by Argenx for Antibody-Mediated Rejection (AMR): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase I for Antibody-Mediated Rejection (AMR). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Antibody-Mediated Rejection (AMR)

Data Insights

Efgartigimod alfa by Argenx for Primary Sjogren's Syndrome: Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Primary Sjogren's Syndrome

Data Insights

Efgartigimod alfa by Argenx for Polymyositis: Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Polymyositis. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Polymyositis

Data Insights

Efgartigimod alfa by Argenx for Tachycardia (Tachyarrhythmias): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Tachycardia (Tachyarrhythmias). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Tachycardia (Tachyarrhythmias)

Data Insights

Efgartigimod alfa by Argenx for Immune Mediated Necrotizing Myopathy (IMNM): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Immune Mediated Necrotizing Myopathy (IMNM). According...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM)

Data Insights

Efgartigimod alfa by Argenx for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval

Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Inflammatory Myopathy (IIM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Idiopathic Inflammatory Myopathy (IIM)